Skip to main content
. 2022 Jun 14;66(7):e00308-22. doi: 10.1128/aac.00308-22

FIG 3.

FIG 3

Pharmacokinetic data of CAMB administration in patients with CMC. (a and b) Plasma concentrations of amphotericin B (in ng/mL) measured over serial time points, as indicated, (a) at day 1 after initiation at 100 mg, (b) at day 14 after continuation at 200 mg/day, and at day 27 after the first dose of the 400 mg twice-daily CAMB dosing for Patients 1, 3, and 4 or after continuation of 200 mg twice daily for Patient 2.